CCO
0.003
50%
FIN
0.005
-28.6%
M2R
0.003
50%
CAN
0.003
-25%
SPX
0.003
50%
KTA
0.004
-20%
TOU
0.003
50%
VIT
0.021
-19.2%
UM1
0.165
37.5%
AVD
0.1
-16.7%
AVE
0.02
33.3%
ENL
0.005
-16.7%
BLU
0.004
33.3%
FEL
0.005
-16.7%
HIQ
0.008
33.3%
IPD
0.005
-16.7%
LKO
0.64
25.5%
BNL
0.006
-14.3%
M2M
0.01
25%
KM1
0.09
-14.3%
MGU
0.005
25%
LIS
0.12
-14.3%
PL9
0.007
16.7%
PET
0.006
-14.3%
SIS
0.007
16.7%
BAK
0.16
-13.5%
YAR
0.007
16.7%
CRD
0.415
-13.5%
BNZ
2.47
16.5%
AAU
0.007
-12.5%
ZNO
0.058
16%
CYP
0.014
-12.5%
SIX
0.081
15.7%
MQR
0.007
-12.5%
PKY
0.059
15.7%
WOA
0.007
-12.5%
MEL
0.016
14.3%
KLV
0.067
-11.8%
PV1
0.008
14.3%
TAS
0.053
-11.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts